1,335 Shares in BeOne Medicines Ltd. – Sponsored ADR $ONC Purchased by Collaborative Fund Advisors LLC

Collaborative Fund Advisors LLC acquired a new position in shares of BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 1,335 shares of the company’s stock, valued at approximately $489,000.

A number of other institutional investors and hedge funds have also bought and sold shares of ONC. Bank of America Corp DE lifted its position in BeOne Medicines by 7.0% during the first quarter. Bank of America Corp DE now owns 405,273 shares of the company’s stock worth $120,354,000 after acquiring an additional 26,441 shares during the last quarter. Baird Financial Group Inc. boosted its holdings in shares of BeOne Medicines by 5.5% during the second quarter. Baird Financial Group Inc. now owns 368,978 shares of the company’s stock worth $105,148,000 after acquiring an additional 19,327 shares during the period. Candriam S.C.A. boosted its holdings in shares of BeOne Medicines by 31.7% during the first quarter. Candriam S.C.A. now owns 259,731 shares of the company’s stock worth $77,132,000 after acquiring an additional 62,470 shares during the period. First Trust Advisors LP grew its position in shares of BeOne Medicines by 91.9% in the first quarter. First Trust Advisors LP now owns 241,426 shares of the company’s stock valued at $71,696,000 after purchasing an additional 115,601 shares during the last quarter. Finally, Jennison Associates LLC grew its position in shares of BeOne Medicines by 102.1% in the first quarter. Jennison Associates LLC now owns 154,465 shares of the company’s stock valued at $45,871,000 after purchasing an additional 78,027 shares during the last quarter. Institutional investors and hedge funds own 48.55% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the company. Weiss Ratings raised BeOne Medicines from a “hold (c+)” rating to a “buy (b-)” rating in a report on Thursday, October 8th. Wolfe Research restated an “outperform” rating and issued a $370.00 price target on shares of BeOne Medicines in a research note on Monday, August 10th. Wall Street Zen raised BeOne Medicines from a “buy” rating to a “strong-buy” rating in a report on Saturday, July 18th. Royal Bank Of Canada increased their price objective on BeOne Medicines from $450.00 to $459.00 and gave the stock an “outperform” rating in a research report on Thursday, October 8th. Finally, Citizens Jmp lifted their target price on BeOne Medicines from $396.00 to $405.00 and gave the stock a “market outperform” rating in a report on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, BeOne Medicines presently has an average rating of “Moderate Buy” and an average price target of $412.26.

BeOne Medicines Trading Up 6.4%

Shares of NASDAQ:ONC opened at $377.78 on Thursday. The business’s 50 day simple moving average is $362.57 and its 200 day simple moving average is $325.73. BeOne Medicines Ltd. – Sponsored ADR has a 1 year low of $253.95 and a 1 year high of $388.66. The company has a debt-to-equity ratio of 0.17, a current ratio of 3.40 and a quick ratio of 3.06. The company has a market capitalization of $41.48 billion, a P/E ratio of 66.51 and a beta of 0.63.

BeOne Medicines (NASDAQ:ONC) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $2.05 earnings per share for the quarter, beating the consensus estimate of $1.40 by $0.65. The firm had revenue of $1.71 billion during the quarter, compared to analysts’ expectations of $1.66 billion. BeOne Medicines had a return on equity of 14.23% and a net margin of 10.70%. On average, research analysts anticipate that BeOne Medicines Ltd. – Sponsored ADR will post 8.99 EPS for the current fiscal year.

Insider Activity at BeOne Medicines

In related news, CEO John Oyler sold 54,892 shares of the business’s stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $358.15, for a total value of $19,659,569.80. Following the completion of the transaction, the chief executive officer owned 240,743 shares of the company’s stock, valued at $86,222,105.45. The trade was a 18.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Xiaodong Wang sold 31,028 shares of the business’s stock in a transaction dated Tuesday, October 27th. The shares were sold at an average price of $362.97, for a total value of $11,262,233.16. Following the completion of the transaction, the insider directly owned 31,028 shares of the company’s stock, valued at approximately $11,262,233.16. This trade represents a 50.00% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 376,373 shares of company stock worth $134,848,154 in the last quarter. 6.19% of the stock is currently owned by corporate insiders.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company focused on discovering, developing, manufacturing and commercializing medicines for cancer patients. Formerly known as BeiGene, the company operates an integrated biotechnology platform spanning research, clinical development, regulatory activities and commercial operations.

Its portfolio includes BRUKINSA (zanubrutinib), a Bruton’s tyrosine kinase inhibitor used in the treatment of several blood cancers, and TEVIMBRA (tislelizumab), an anti-PD-1 immunotherapy approved in multiple markets for certain cancers.